MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

2 years ago

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD…

BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University

2 years ago

VANCOUVER, British Columbia, March 04, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF…

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

2 years ago

CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device…

Elixirgen Therapeutics Presents Preclinical Data with Bobcat mRNATM Technology in Duchenne Muscular Dystrophy at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

2 years ago

Bobcat mRNATM technology is a novel linear mRNA platform able to encode large proteins Data showed restoration of muscular function…

Tome Biosciences Forms Science and Technology Advisory Committee

2 years ago

WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, announces the formation…

4DMT to Participate in Upcoming Investor Conferences

2 years ago

EMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic…

Aruna BIO Establishes Stroke Advisory Board to Advance Lead Program, AB126 into the Clinic

2 years ago

-The Stroke Advisory Board brings together distinguished experts in neurology and stroke to support the advancement of its neural exosome…

RushNet Names Arizona Businessman Michael Cunha as Chairman and Chief Executive Officer

2 years ago

PHOENIX, AZ / ACCESSWIRE / March 4, 2024 / RushNet, Inc (OTC PINK:RSHN), (the "Company") announced today the appointment of…

MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder

2 years ago

Ethics and regulatory approvals finalized for world-first take-home use of a psychedelic medicine MB22001 in placebo-controlled trial in depressed patients…

Redeye Initiates Coverage of PMD Device Solutions

2 years ago

STOCKHOLM, SE / ACCESSWIRE / March 04, 2024 / PMD Device Solutions (STO:PROMO) (FRA:8T0) Redeye assigns a base-case valuation of…